Premium fitness club Life Time (NYSE:LTH) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 18.7% year on year to $663.3 million. The company’s full-year revenue guidance of $2.95 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $0.27 per share was 30.1% above analysts’ consensus estimates.
Golf equipment and apparel company Acushnet (NYSE:GOLF) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.8% year on year to $445.2 million. The company’s full-year revenue guidance of $2.51 billion at the midpoint came in 1.3% below analysts’ estimates. Its GAAP loss of $0.02 per share was 93.9% above analysts’ consensus estimates.
Medical technology company Teleflex (NYSE:TFX) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 2.8% year on year to $795.4 million. Its non-GAAP profit of $3.89 per share was in line with analysts’ consensus estimates.
Shares of Snowflake surged 13% in premarket trading Thursday, a day after the cloud software provider reported better-than-estimated results and a buoyant outlook on booming demand for artificial intelligence products.
Cabinet manufacturing company American Woodmark (NASDAQ:AMWD) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 5.8% year on year to $397.6 million. Its non-GAAP profit of $1.05 per share was 20.2% below analysts’ consensus estimates.
Higher education company Strategic Education (NASDAQ:STRA) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.9% year on year to $311.5 million. Its non-GAAP profit of $1.27 per share was 2.4% above analysts’ consensus estimates.
Cathie Wood is a top investor to watch, thanks in large part to her focus on owning disruptive and innovative businesses operating within cutting-edge technologies. Ark Invest, the firm she runs, offers numerous exchange-traded funds (ETFs) for investors looking to gain exposure. Wood is known for making bold predictions that catch a lot of attention.
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $198.6 million. On the other hand, the company expects next quarter’s revenue to be around $203 million, close to analysts’ estimates. Its non-GAAP profit of $0.09 per share was in line with analysts’ consensus estimates.
WPP's CEO Mark Read noted that the revenue slip was partly due to “weaker client discretionary spend.”
Healthcare tech company Privia Health Group (NASDAQ:PRVA) announced better-than-expected revenue in Q4 CY2024, with sales up 4.6% year on year to $460.9 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.21 per share was in line with analysts’ consensus estimates.
